GLP-2 enhances barrier formation and attenuates TNFα-induced changes in a Caco-2 cell model of the intestinal barrier

Regulatory Peptides

Volumn 178, Issue 1-3, 2012, Pages 95-101

  Moran, G W ^a   O'Neill, C ^a   Mclaughlin, J T ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

GLP 2; Inflammatory bowel disease; Intestinal permeability; Tight junction proteins

Indexed keywords

GLUCAGON LIKE PEPTIDE 2; OCCLUDIN; PROTEIN ZO1;

ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; IMMUNOBLOTTING; INTESTINE MUCOSA PERMEABILITY; MEMBRANE FORMATION; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; TIGHT JUNCTION;

CACO-2 CELLS; CLAUDIN-1; CLAUDIN-4; ELECTRIC IMPEDANCE; GLUCAGON-LIKE PEPTIDE 2; HUMANS; INTESTINAL MUCOSA; OCCLUDIN; TIGHT JUNCTIONS; TUMOR NECROSIS FACTOR-ALPHA; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84865348154     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2012.07.002     Document Type: Article

References (42)

1. Van Itallie C.M., Anderson J.M. Claudins and epithelial paracellular transport. Annu Rev Physiol 2006, 68:403-429.
2. Furuse M., Tsukita S. Claudins in occluding junctions of humans and flies. Trends Cell Biol 2006, 16:181-188.
3. Angelow S., Ahlstrom R., Yu A.S. Biology of claudins. Am J Physiol Renal Physiol 2008, 295:F867-F876.
4. Gitter A.H., Bendfeldt K., Schmitz H., Schulzke J.D., Bentzel C.J., Fromm M. Epithelial barrier defects in HT-29/B6 colonic cell monolayers induced by tumor necrosis factor-alpha. Ann N Y Acad Sci 2000, 915:193-203.
5. McKay D.M., Singh P.K. Superantigen activation of immune cells evokes epithelial (T84) transport and barrier abnormalities via IFN-gamma and TNF alpha: inhibition of increased permeability, but not diminished secretory responses by TGF-beta2. J Immunol 1997, 159:2382-2390.
6. Mullin J.M., Snock K.V. Effect of tumor necrosis factor on epithelial tight junctions and transepithelial permeability. Cancer Res 1990, 50:2172-2176.
7. Ma T.Y., Iwamoto G.K., Hoa N.T., Akotia V., Pedram A., Boivin M.A., et al. TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation. Am J Physiol Gastrointest Liver Physiol 2004, 286:G367-G376.
8. Li N., Gu L., Qu L., Gong J., Li Q., Zhu W., et al. Berberine attenuates pro-inflammatory cytokine-induced tight junction disruption in an in vitro model of intestinal epithelial cells. Eur J Pharm Sci 2010, 40:1-8.
9. Costantini T.W., Deree J., Loomis W., Putnam J.G., Choi S., Baird A., et al. Phosphodiesterase inhibition attenuates alterations to the tight junction proteins occludin and ZO-1 in immunostimulated Caco-2 intestinal monolayers. Life Sci 2009, 84:18-22.
10. Hollander D., Vadheim C., Brettholz E., Petersen G., Delahunty T., Rotter J. Increased intestinal permeability in patients with Crohn's disease and their relatives. Ann Intern Med 1986, 105:883-885.
11. Katz K., Hollander D., Vadheim C., McElree C., Delahunty T., Dadufalza D., et al. Intestinal permeability in patients with Crohn's disease and their healthy relatives. Gastroenterology 1989, 97:927-931.
12. May G., Sutherland L., Meddings J. Is small intestinal permeability really increased in relatives of patients with Crohn's disease?. Gastroenterology 1993, 104:1627-1632.
13. Ukabam S., Clamp J., Cooper B. Abnormal small intestinal permeability to sugars in patients with Crohn's disease of the terminal ileum and colon. Digestion 1983, 27:70-74.
14. Schmitz H., Barmeyer C., Fromm M., Runkel N., Foss H.D., Bentzel C.J., et al. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology 1999, 116:301-309.
15. Heller F., Florian P., Bojarski C., Richter J., Christ M., Hillenbrand B., et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005, 129:550-564.
16. Poritz L.S., Harris L.R., Kelly A.A., Koltun W.A. Increase in the tight junction protein claudin-1 in intestinal inflammation. Dig Dis Sci 2011, 56(10):2802-2809.
17. Prasad S., Mingrino R., Kaukinen K., Hayes K.L., Powell R.M., MacDonald T.T., et al. Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab Invest 2005, 85:1139-1162.
18. Zeissig S., Burgel N., Gunzel D., Richter J., Mankertz J., Wahnschaffe U., et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut 2007, 56:61-72.
19. Jasleen J., Ashley S.W., Shimoda N., Zinner M.J., Whang E.E. Glucagon-like peptide 2 stimulates intestinal epithelial proliferation in vitro. Dig Dis Sci 2002, 47:1135-1140.
20. Bulut K., Meier J.J., Ansorge N., Felderbauer P., Schmitz F., Hoffmann P., et al. Glucagon-like peptide 2 improves intestinal wound healing through induction of epithelial cell migration in vitro-evidence for a TGFbeta-mediated effect. Regul Pept 2004, 121:137-143.
21. Boushey R.P., Yusta B., Drucker D.J. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol 1999, 277:E937-E947.
22. Lovshin J., Drucker D.J. New frontiers in the biology of GLP-2. Regul Pept 2000, 90:27-32.
23. Liu X., Nelson D.W., Holst J.J., Ney D.M. Synergistic effect of supplemental enteral nutrients and exogenous glucagon-like peptide 2 on intestinal adaptation in a rat model of short bowel syndrome. Am J Clin Nutr 2006, 84:1142-1150.
24. Martin G.R., Beck P.L., Sigalet D.L. Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation. World J Gastroenterol 2006, 12:4117-4129.
25. Jeppesen P.B. Glucagon-like peptide-2: update of the recent clinical trials. Gastroenterology 2006, 130:S127-S131.
26. McLaughlin J., Padfield P.J., Burt J.P., O'Neill C.A. Ochratoxin A increases permeability through tight junctions by removal of specific claudin isoforms. Am J Physiol Cell Physiol 2004, 287:C1412-C1417.
27. Bravo S.A., Nielsen C.U., Amstrup J., Frokjaer S., Brodin B. In-depth evaluation of Gly-Sar transport parameters as a function of culture time in the Caco-2 cell model. Eur J Pharm Sci 2004, 21:77-86.
28. Ye D., Ma I., Ma T.Y. Molecular mechanism of tumor necrosis factor-alpha modulation of intestinal epithelial tight junction barrier. Am J Physiol Gastrointest Liver Physiol 2006, 290:G496-G504.
29. Drucker D.J., Yusta B., Boushey R.P., DeForest L., Brubaker P.L. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol 1999, 276:G79-G91.
30. L'Heureux M.C., Brubaker P.L. Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis. J Pharmacol Exp Ther 2003, 306:347-354.
31. Sigalet D.L., Wallace L.E., Holst J.J., Martin G.R., Kaji T., Tanaka H., et al. Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 2007, 293:G211-G221.
32. Ko J.A., Murata S., Nishida T. Up-regulation of the tight-junction protein ZO-1 by substance P and IGF-1 in A431 cells. Cell Biochem Funct 2009, 27:388-394.
33. Ko J.A., Yanai R., Nishida T. Up-regulation of ZO-1 expression and barrier function in cultured human corneal epithelial cells by substance P. FEBS Lett 2009, 583:2148-2153.
34. Umeda K., Ikenouchi J., Katahira-Tayama S., Furuse K., Sasaki H., Nakayama M., et al. ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation. Cell 2006, 126:741-754.
35. Raleigh D.R., Boe D.M., Yu D., Weber C.R., Marchiando A.M., Bradford E.M., et al. Occludin S408 phosphorylation regulates tight junction protein interactions and barrier function. J Cell Biol 2011, 193:565-582.
36. Chasiotis H., Wood C.M., Kelly S.P. Cortisol reduces paracellular permeability and increases occludin abundance in cultured trout gill epithelia. Mol Cell Endocrinol 2010, 323:232-238.
37. Benjamin M.A., McKay D.M., Yang P.C., Cameron H., Perdue M.H. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 2000, 47:112-119.
38. Poritz L.S., Garver K.I., Green C., Fitzpatrick L., Ruggiero F., Koltun W.A. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. J Surg Res 2007, 140:12-19.
39. Fries W., Muja C., Crisafulli C., Cuzzocrea S., Mazzon E. Dynamics of enterocyte tight junctions: effect of experimental colitis and two different anti-TNF strategies. Am J Physiol Gastrointest Liver Physiol 2008, 294:G938-G947.
40. Alavi K., Schwartz M.Z., Palazzo J.P., Prasad R. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. J Pediatr Surg 2000, 35:847-851.
41. Arthur G.L., Schwartz M.Z., Kuenzler K.A., Birbe R. Glucagonlike peptide-2 analogue: a possible new approach in the management of inflammatory bowel disease. J Pediatr Surg 2004, 39:448-452.
42. Buchman A.L., Katz S., Fang J.C., Bernstein C.N., Abou-Assi S.G. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm Bowel Dis 2010, 16:962-973.